Secondary malignant neoplasm of pleura
ICD-10 C78.2 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of pleura.
C78.2 refers to secondary malignant neoplasms of the pleura, which are metastatic tumors that have spread to the pleural space from a primary malignancy located elsewhere in the body. The pleura is a double-layered membrane surrounding the lungs, and when cancer cells from another site invade this area, it can lead to pleural effusion, chest pain, and respiratory difficulties. Common primary cancers that metastasize to the pleura include lung, breast, and ovarian cancers. The diagnosis often involves imaging studies such as CT scans or MRIs, and may require a biopsy to confirm the presence of malignant cells. Staging of the disease is crucial, as it helps determine the extent of the metastasis and guides treatment options. Palliative care considerations are essential for managing symptoms and improving the quality of life for patients, particularly in advanced stages where curative treatment may not be feasible. Understanding the patient's overall health status and preferences is vital in developing a comprehensive care plan.
Clear documentation of the primary cancer diagnosis, staging, and treatment plan.
Patients with known primary cancers presenting with pleural effusions or respiratory symptoms.
Ensure that the metastatic nature of the disease is well-documented to avoid misclassification.
Detailed respiratory assessments and imaging results to support the diagnosis of pleural involvement.
Patients with respiratory distress due to pleural effusion secondary to malignancy.
Documenting the extent of pleural involvement and any interventions performed.
Used when a patient with C78.2 presents with pleural effusion requiring drainage.
Document the indication for the procedure, including symptoms and imaging findings.
Pulmonologists should ensure that the procedure is justified based on clinical findings.
Accurate coding of C78.2 is crucial for appropriate treatment planning, reimbursement, and tracking of cancer outcomes. It ensures that patients receive the necessary palliative care and interventions for their metastatic disease.
